London‑based Medicxi announced the close of its fifth fund, Medicxi V, raising €500 million to invest in asset‑centric biotech companies. The oversubscribed fund continues Medicxi’s strategy of creating and backing single‑asset companies and follows a track record of portfolio exits and positive clinical readouts. Partner Giovanni Mariggi and the Medicxi team emphasized capital efficiency and concentrated resource allocation to advance clear product candidates. The fund will support company building across therapeutic areas and leverages prior exits and buyouts in the firm’s portfolio as proof points for its model. The raise signals sustained investor appetite for focused biotech strategies in Europe and more capital flowing to translational, asset‑driven startups.